Bernina BioInvest

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of RNA-based drugs aimed at modulating protein expression and cellular targeting. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, enhancing the precision and effectiveness of treatments. The company focuses on regenerative medicine, particularly in dermatology, oncology, and myology, and is actively developing lead candidate programs for conditions such as stress urinary incontinence, solid tumors, and rare diseases. Currently, Versameb is progressing towards its first in-human proof-of-concept clinical study while continuing to advance its innovative platform.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of RNA-based drugs aimed at modulating protein expression and cellular targeting. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, enhancing the precision and effectiveness of treatments. The company focuses on regenerative medicine, particularly in dermatology, oncology, and myology, and is actively developing lead candidate programs for conditions such as stress urinary incontinence, solid tumors, and rare diseases. Currently, Versameb is progressing towards its first in-human proof-of-concept clinical study while continuing to advance its innovative platform.

Eldico Scientific AG, founded in 2019 and based in Villigen, Switzerland, specializes in the development and manufacturing of electron diffractometers designed for the analysis of solid compounds. The company's innovative instruments enable researchers in various fields, including pharmaceuticals, agrochemicals, and advanced materials, to characterize nano-crystalline systems that were previously difficult to measure. By providing tools for nano-crystallographic investigations, Eldico aims to enhance the efficiency and cost-effectiveness of structural information gathering, thereby accelerating the drug discovery and development process. The company has made significant strides in the field, achieving proof of concept for its technology in collaboration with leading Swiss research institutions, and has received recognition for its contributions to scientific advancement.

ARTIDIS AG, founded in 2014 and based in Basel, Switzerland, specializes in developing tissue diagnostic solutions aimed at personalizing cancer therapy. The company offers Automated Reliable Tissue Diagnostics (ARTIDIS), a nanomechanical diagnostic tool that analyzes tissue samples from biopsies. This innovative technology employs a nanomechanical sensor to assess the physical properties of tissue, enabling clinicians to distinguish between benign and malignant tissues within three hours. Additionally, ARTIDIS's platform can evaluate the aggressiveness of tumors with high precision by measuring the nanomechanical signatures of cells. The approach focuses on identifying soft cells, which are responsible for metastasis in cancer. Beyond oncology, ARTIDIS's technology has broader applications, capable of analyzing various types of living tissues. This combination of nanotechnology and advanced analytics facilitates non-destructive biopsy analysis and provides actionable insights for treatment at the patient's bedside.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Versameb AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2018. The company specializes in the research and development of RNA-based drugs aimed at modulating protein expression and cellular targeting. Versameb's proprietary technology platform, VERSagile, allows for the simultaneous influence of multiple therapeutic targets through a single molecular construct, enhancing the precision and effectiveness of treatments. The company focuses on regenerative medicine, particularly in dermatology, oncology, and myology, and is actively developing lead candidate programs for conditions such as stress urinary incontinence, solid tumors, and rare diseases. Currently, Versameb is progressing towards its first in-human proof-of-concept clinical study while continuing to advance its innovative platform.

InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drug discovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials.